See Supplemental Patient Information
- Some infected patients may not have a delayed hypersensitivity reaction to a tuberculin test. These include patients with viral infections (measles, mumps, chickenpox, HIV), bacterial infections, and fungal infections; patients taking certain drugs (corticosteroids and other immunosuppressive agents); patients with metabolic derangements (chronic renal failure), low protein states, young or older age, stress (surgery, burns, mental illness, graft-versus-host reactions), diseases affecting lymphoid organs (Hodgkin's disease, lymphoma, chronic leukemia, sarcoidosis), and malignancy; and those receiving live virus vaccinations
- In HIV-infected individuals, screening of tuberculin skin-test should be completed as early as possible because results are less reliable as CD4 counts decline in such patients
- Do not administer IM/IV/SC injection
- Individuals infected with other mycobacteria, including vaccination with BCG may show a false positive tuberculin test
- Asses patient's current health status and medical history related to the immunization and sensitivity to components prior to administration
- In case of a rare anaphylatic reaction following the administration of therapy, immediate medical treatment such as epinephrine injection (1:1,000) with other appropriate agents should be readily available
- To prevent transmission of other infectious agents from person to person, use a separate, sterile syringe and needle or a sterile disposable unit for each patient
- Special care should be taken to ensure the product is given intradermally and on the volar aspect of the forearm
Supplemental Patient Information
- Occurrence of adverse events such as vesiculation, ulceration or necrosis at the test site should be reported to health-care provider
Pregnancy Category:C
Breastfeeding: There is no reason to withhold breastfeeding after tuberculosis skin testing or to avoid skin testing in nursing mothers. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT).
US Trade Name(s)
US Availability
Tubersol
- INJ: 5 TU/0.1 mL (1, 5 mL vial)
tuberculin ppd [Intradermal] (generic)
- INJ: 5 TU/0.1 mL (1, 5 mL vial)
Canadian Trade Name(s)
Canadian Availability
Tubersol
- INJ: 5 TU/0.1 mL (1, 5 mL vial)
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
tuberculin ppd
- INJ: 100 IU (0.002 mg)/mL (1,10 mL vial )
[Outline]
